Skip to Main Content

August 05, 2022  
Health Law Weekly

Seventh Circuit Nixes Antitrust Action over AbbVie’s Humira Patents

  • August 05, 2022

The Seventh Circuit rejected August 1 an action by indirect purchasers of the blockbuster biologic Humira against AbbVie Inc. alleging it violated the antitrust laws by establishing a “patent thicket” for the drug that kept would-be competitors from risking market entry.


You must be logged in to access this content.